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BDNF val66met affects hippocampal volume and
emotion-related hippocampal memory activity
ML Molendijk1,2,8, M-J van Tol2,3,4,8, BWJH Penninx3,5,6, NJA van der Wee2,3, A Aleman4,7, DJ Veltman6, P Spinhoven1,2,3
and BM Elzinga1,2
The val66met polymorphism on the BDNF gene has been reported to explain individual differences in hippocampal volume and
memory-related activity. These findings, however, have not been replicated consistently and no studies to date controlled for the
potentially confounding impact of early life stress, such as childhood abuse, and psychiatric status. Using structural and
functional MRI, we therefore investigated in 126 depressed and/or anxious patients and 31 healthy control subjects the effects of
val66met on hippocampal volume and encoding activity of neutral, positive and negative words, while taking into account
childhood abuse and psychiatric status. Our results show slightly lower hippocampal volumes in carriers of a met allele (n¼ 54)
relative to val/val homozygotes (n¼ 103) (P¼ 0.02, effect size (Cohen’s d)¼ 0.37), which appeared to be independent of
childhood abuse and psychiatric status. For hippocampal encoding activity, we found a val66met–word valence interaction
(P¼ 0.02) such that carriers of a met allele showed increased levels of activation in response to negative words relative to
activation in the neutral word condition and relative to val/val homozygotes. This, however, was only evident in the absence of
childhood abuse, as abused val/val homozygotes showed hippocampal encoding activity for negative words that was
comparable to that of carriers of a met allele. Neither psychiatric status nor memory accuracy did account for these associations.
In conclusion, BDNF val66met has a significant impact on hippocampal volume independently of childhood abuse and
psychiatric status. Furthermore, early adverse experiences such as childhood abuse account for individual differences in
hippocampal encoding activity of negative stimuli but this effect manifests differently as a function of val66met.
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Introduction
Brain-derived neurotrophic factor (BDNF) regulates the
sprouting of axons and dendrites in the hippocampus, a key
structure for emotion and memory processing.1–4 Rodent
studies, for example, have shown that BDNF modulates
hippocampal neuronal differentiation5 and hippocampal
dependent memory.6–8 Moreover, human studies have
reported a positive relation between BDNF concentration,
hippocampal volume and memory performance.9,10
Studies focusing on a single nucleotide site in the DNA
sequence of the BDNF gene; val66met (a valine (val) to
methionine (met) insertion at codon 66) have partly confirmed
the associations of BDNF protein expression with neurobio-
logical and behavioral abnormalities. Egan et al.11 showed
in vitro that the met allele is linked to a reduced activity-
dependent expression of BDNF in hippocampal neurons of
rats, a finding that was replicated by Chen et al.12 In addition,
studies have shown that in the hippocampus the met allele is
associated with diminished levels of N-acetyl-aspartate, a
putative marker for neuronal integrity.11,13 In line with these
findings, some studies have shown that the met allele is
associated with impaired episodic memory11 and executive
functioning.14,15 Structural and functional magnetic reso-
nance imaging (MRI) studies further suggest that carriers of
a met allele have smaller hippocampal volumes relative to val/
val homozygotes16–19 and altered hippocampal activity during
the encoding of stimuli.11,20 Nevertheless, these findings have
not been consistently replicated,21–26 which might be due to
the inclusion of small samples and task characteristics such
as the emotional valence of the stimuli. Furthermore, the
occurrence of early trauma, such as childhood abuse and
psychiatric status, represent sources of variation in hippo-
campal volume and function (reviewed in refs. 4,27) that have
not been taken into account in previous studies. In addition,
gene–environment interactions have been reported between
BDNF val66met and abuse on brain structure and activity.28,29
As a consequence, the earlier reported associations between
BDNF val66met locus and hippocampal structure and function
might be (partly) dependent on a history of childhood abuse or
on psychiatric status.
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The goal of this study, then, was to evaluate the effects
of val66met on hippocampal volume and on encoding-related
hippocampal activity while taking into account the potential
influence of childhood abuse and diagnostic status. Given
earlier conflicting findings,11,20 we further aimed to extend
previous findings by examining the effects of neutral, positive
and negative emotional stimuli on hippocampal activity.
Materials and methods
Subjects. The data analyzed are from the imaging sample
of the Netherlands Study of Depression and Anxiety
(NESDA).30,31 Included in the NESDA imaging sample
were 301 subjects, of whom 233 were patients with a
current depressive and/or anxiety disorder and 68 healthy
control subjects. Genetic and high-quality functional and
structural MRI data were available for 157 persons who
participated in the NESDA MRI study of whom 126 were
depressed and/or anxious patients and 31 were healthy
controls. Subjects in the current study did not differ from
subjects in the NESDA imaging sample (N¼ 301) with regard
to age (P¼ 0.98), gender (P¼ 0.22) and current diagnosis
(P¼ 0.07).
Subjects underwent imaging at three different locations in
the Netherlands: Academic Medical Center (AMC), University
of Amsterdam, University Medical Center Groningen (UMCG)
and Leiden University Medical Center (LUMC). To be eligible,
subjects had to be 18–57 years of age and fluent in Dutch.
Exclusion criteria were having an Axis-I disorder other than a
depressive and/or anxiety disorder (Diagnostic and Statistical
Manual of Mental disorders fourth edition (DSM-IV),32 being
on antidepressant treatment other than selective serotonin
reuptake inhibitors (SSRIs) at a stable dose,33 a history of a
major internal or neurological disorder, dependency on
alcohol and/or drugs, smoking 45 cigarettes a day, or
hypertension (4180/130 mm Hg). The protocol and proce-
dures were approved by each of the ethical committees of
participating institutes and all subjects signed an informed
consent.
Diagnoses of depressive and anxiety disorders were
established according to the criteria set forth in the DSM-
IV32 on the basis of responses to the Composite International
Diagnostic Interview 2.1 (CIDI) lifetime version,34 a reliable
and validated diagnostic tool.35 The severity of depressive
and anxiety symptoms was assessed with the Montgomery
A˚sberg Depression Rating Scale (MA˚DRS)36 and the Beck
Anxiety Inventory (BAI),37 both of which have been shown to
have excellent psychometric characteristics.38,39
Childhood abuse was assessed retrospectively using a
semi-structured childhood trauma interview.40,41 In this inter-
view, participants were asked whether they had experienced
emotional neglect or psychological abuse, physical abuse
and/or sexual abuse before the age of 16 years. After an
affirmative answer, subjects were asked for details on the
frequency of the events. Based on the sum and the frequency
of abusive events an index (range 0–8) was calculated for
each subject (for details see Wiersma et al.42).
Genotyping was performed by Perlegen Sciences
(Mountain View, CA, USA). For a detailed description of the
procedures according to which genotyping was performed, we
refer to Boomsma et al.43 Val66met was extracted from whole-
genome data using PLINK software version 1.07 (http://
pngu.mgh.harvard.edu/~purcell/plink). In our sample, 103
subjects were val/val homozygotes (65.6%) and 54 subjects
carried a met allele (34.4%). Two subjects (1.3%) with the
met/met genotype were merged with heterozygous subjects
into a group of met allele carriers. Genotype counts were 82
val66val, 42 val66met and 2 met66met in the patient group and
21 val66val, 10 val66met and 0 met66met in the healthy control
group. Patient and healthy control samples did not differ with
regard to genotype distribution (P¼ 0.77). Allele frequencies
were in Hardy–Weinberg equilibrium in the GAIN-MDD
sample in which the genotyping was performed (N¼ 3530,
w1
2¼ 0.62, P¼ 0.43) and in the sub-sample on which we
present data (n¼ 157, w12¼ 2.66, P¼ 0.10).
Memory paradigm. In the scanner, subjects performed a
subject-paced, event-related encoding task, similar to the
paradigm described by Daselaar et al.44 and known to
reliably activate the hippocampus. The task is described in
detail elsewhere.45 Briefly, during the encoding phase of the
task 120 words (40 of neutral valence, 40 of positive valence
and 40 of negative valence) were presented in pseudo-
randomized order. Subjects were instructed to classify these
words according to valence. After a 10-minute retention
interval, subjects were asked to complete a word recognition
task. Subjects were instructed to indicate whether they had
seen or probably had seen the word or whether the word was
new. Discriminant accuracy was calculated as the proportion
correctly recognized words minus the proportion false
alarms.45
Image acquisition and data handling. Image acquisition
and data handling are detailed elsewhere.31,45 In sum,
imaging data were collected using Philips 3-Tesla MRI
scanners (Best, the Netherlands) using SENSE-6 and 8
channel head coils (AMC and UMCG/LUMC, respectively).
Echo-planar images were obtained using a T2*-weighted
gradient echo sequence with repetition time 2300 ms, a
30 ms echo time (UMCG 28 ms), a matrix size of 96 96
(UMCG 64 64), producing 35 axial slices of 3 mm thickness
direction interleaved, 2.29 2.29 mm2 in-plain resolution
(UMCG 3 3). Anatomical imaging included a sagittal 3-D
gradient-echo T1-weighted sequence with a repetition
time of 9 ms and a 3.5 ms echo time acquiring slices with a
voxel size of 1 1 1 mm3. Imaging data were preprocessed
with SPM5 (Statistic Parametric Mapping, http://
www.fil.ion.ucl.ac.uk/spm/).
Preprocessing of the data included reorientation of the
functional images to the anterior commissure, slice time
correction, image realignment, registration of the T1-scan to
the mean image, warping to Montreal Neurological Institute
(MNI) space as defined by the SPM5 T1-template, reslicing to
3 3 3 mm3 voxels, and spatial smoothing using an 8-mm
FWHM Gaussian kernel. Haemodynamic responses to each
stimulus were modeled with a delta function convolved with a
synthetic haemodynamic response function and modulated
using response times.
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Contrast images for ‘subsequent hits vs baseline’ were
calculated for the neutral, positive and negative word
condition per subject on a voxel-by-voxel basis, based on
subsequent recognition success and entered in a 2 (group:
val/val homozygotes vs met carriers; independent factor) by 3
(condition: neutral, positive, negative (4baseline); dependent
factor) MANCOVA with age, education and scan center as
covariates. Mean BOLD signal change during successful
encoding in the left and right hippocampus was extracted per
condition (neutral/positive/neutral4baseline) using the
MARSBAR toolbox.46 The hippocampal masks of the Auto-
mated Anatomical Labeling software package, implemented
in the WFU Pick Atlas toolbox47 were used to define the left
and right hippocampal region.
Anatomical images were processed using an optimized
voxel-based morphometry approach, following the Diffeo-
morphic Anatomical Registration Through Exponentiated Lie
algebra (DARTEL)48 using SPM5 software implemented in
Matlab 7.1.0 (The MathWorks, Natick, MA, USA). For details
see van Tol et al.45 To test for differences in regional brain
volume, an independent samples t-test was set up for a voxel-
wise comparison of the gray matter density images of the val/
val homozygotes and met carriers, with age, scan center and
total gray matter volume as covariates. Following a similar
approach as for signal change extraction, the mean volume of
the left and right hippocampus was additionally extracted,
again using the binary masks of the hippocampus based on
the Anatomical Automatic Labelling atlas. Data were exported
to SPSS 18.0 (Chicago, IL, USA) for further analysis.
Statistical analyses. Computations were performed in
SPSS 18.0. A P-value of o0.05 (2-tailed) was considered
as the threshold for statistical significance. Demographical
and clinical characteristics between val/val homozygotes and
carriers of a met allele were compared using Student’s t-tests
for continuous- and w2-tests for categorical data.
Main effects of val66met on right, left and total hippocampal
volume were calculated using a Repeated Measures (RM)
ANCOVA with left vs right hippocampal volume as the within-
subjects factor and age, gender, number of years of
education, SSRI use (no vs yes), alcohol use (no vs yes),
scan site and total gray matter volume as covariates.
ANCOVAs were used to assess the effects of val66met on
memory accuracy and hippocampal activity during the
encoding of neutral, positive and negative words. To address
val66met–valence interactions effects on memory accuracy
and hippocampal encoding activity, we ran RM ANCOVAs
with word valence (positive vs neutral and negative vs neutral)
as within-subject factor and age, gender, number of years of
education, SSRI use (no vs yes), alcohol use (no vs yes), scan
site, hippocampal volume, memory accuracy and handed-
ness as covariates. If indicated by between-group differences
in memory accuracy, accuracy scores were included as
covariates in the analyses on hippocampal encoding activity.
Possible interaction effects of val66met with abuse and
diagnosis (dummy variables coding for healthy, depressed,
depressed-anxious and anxious) on hippocampal volume,
memory accuracy and hippocampal encoding activity were
evaluated using hierarchical stepwise regression analyses, if
indicated by statistically significant associations in the above
described analyses. Regression analyses consisted of three
steps: (1) covariates (see above), (2) val66met, childhood
abuse and diagnosis and (3) the interaction terms val66met
abuse and val66met diagnosis. Analyses were rerun with
lifetime instead of current diagnosis (6-month recency).
Tolerance of the predictors and normality of error variances
were verified.
To assess regional specificity of val66met within the
hippocampus and to explore effects of val66met on other
brain regions, voxel-wise analyses were repeated on the
whole brain gray matter density maps and contrast maps
reflecting encoding related activity using SPM5, with the
threshold set at Po0.001, uncorrected. Uncorrected
whole brain results are reported in the supplement. For
regions outside the hippocampus, a threshold of Po0.05,
FWE corrected was set.
Results
The overall sample (N¼ 157) had a mean age of
37.39±10.08 years and included 100 women (63.7%).
Demographical and clinical characteristics of the sample are
given in Table 1 by BDNF genotype. There were no
statistically significant differences between the genotype
groups in terms of demographical and clinical variables.
Furthermore, val66met was not differentially associated with
exposure to childhood abuse (dichotomous (yes vs no), nor
with exposure to specific types of childhood abuse (all
P’s40.75).
BDNF val66met and hippocampal volume. Total
hippocampal volume was smaller in carriers of a met allele
relative to val/val homozygotes (F1,180¼ 5.33, P¼ 0.02). The
effect size of this difference (standardized Cohen’s d, that is,
the mean between-group difference divided by the pooled
standard deviation)49 was 0.38 (see Figure 1 and Table 2 for
covariate adjusted means on total, right and left hippocampal
volume ±s.e.m. No interaction of val66met right vs left
hippocampus was observed (P¼ 0.63). BDNF val66met had
no effect on total gray matter volume (P¼ 0.60). Voxelwise
analyses in SPM5 confirmed these findings, with the peak
voxel located in the posterior part of the hippocampus
(MNI coordinate: Right hippocampus: (x¼ 18, y¼33, z¼ 8
and x¼ 21, y¼30, z¼4), Z¼ 3.61/3.42, k¼ 29/17,
PFWE_ROI¼ 0.018; Left hippocampus: (x¼18, y¼36,
z¼ 8), Z¼ 3.17, k¼ 4, PFWE_ROI¼ 0.062).
Regression analyses were used to evaluate whether the
smaller hippocampal volume in met carriers as compared with
val/val homozygotes were moderated by the effects of abuse
or diagnostic status. Main effects of childhood abuse and
psychiatric status, and interaction effects of val66met with
childhood abuse and psychiatric status on hippocampal
volume were not observed (all P’s40.10). The main effect
of val66met remained statistically significant after the inclusion
of childhood abuse and psychiatric status in the model
(B¼0.13, 95% confidence interval (CI)¼0.24 to 0.02,
P¼ 0.02). Similar results were obtained in analyses with
lifetime instead of current diagnosis and in analysis in which
continuous measures for childhood abuse and depression
severity (that is, total MA˚DRS score) were included as
BDNF val66met affects hippocampal volume and activity
ML Molendijk et al
3
Translational Psychiatry
predictors (data not shown). No effect of BDNF val66met was
observed on other structures at the set threshold (see
Supplementary Table 1).
BDNF val66met and task performance. There were no
overall differences in discriminant accuracy as a function of
genotype (covariate adjusted means±se: val/val
homozygotes¼ 0.57±0.01 vs met carriers¼ 0.58±0.02;
P¼ 0.85). Interaction effects of val66met and word valence
on memory accuracy were not observed, either (all
P’s40.10). Furthermore, memory accuracy was unrelated
to hippocampal volume (Pearson’s r¼ 0.13; P¼ 0.10) and to
hippocampal encoding activity (r¼ 0.04; P¼ 0.66).
BDNF val66met and hippocampal activity. Main effects of
val66met and word valence on hippocampal activity during
the encoding of neutral and positive words were not
observed (see Table 2). However, val66met interacted with
neutral vs negative word valence (P¼ 0.02) such that
hippocampal activity was higher in carriers of a met allele
in the negative word condition relative val/val homozygotes
(P¼ 0.05, Bonferroni corrected (P¼NS) and to hippocampal
activity in the neutral word condition (P¼ 0.002, Bonferroni
corrected (P¼ 0.01). This was not observed in val/val
homozygotes (see Figure 2a and Table 2 for covariate
adjusted means±se by word valence). No val66met-neutral
vs positive word valence interaction effect on encoding
activity was found (P¼ 0.17). Effects of lateralization
Figure 1 (a) Scattergram of total hippocampal volume for subjects homozygous for the val allele (val/val, n¼ 103) and carriers of a met allele (val/met, n¼ 54). Horizontal
lines indicate the mean for each group. Data are adjusted for age, gender, number of years of education, selective serotonin reuptake inhibitor use, alcohol use and scan site.
(b) Coronal and sagittal views and a statistical map of t-transformed hippocampal volume differences by BDNF val66met genotype. Note: voxelwise analyses confirmed these
findings with the peak voxel located in the posterior part of the hippocampus (MNI coordinate: right hippocampus: (x¼ 18, y¼33, z¼ 8 and x¼ 21, y¼30, z¼4),
Z¼ 3.61/3.42, k¼ 29/17; left hippocampus: (x¼18, y¼36, z¼ 8), Z¼ 3.17, k¼ 4).
Table 1 Demographic and clinical characteristics (mean±s.d. or percentages) by BDNF genotype
val66val (n¼ 103) val66met (n¼54) P-value
Females (%) 64.1 (n¼ 66) 63.0 (n¼34) 0.89
Age 37.13±9.61 37.89±10.39 0.65
Education (years) 12.43±3.00 12.63±3.28 0.70
Smoker (%) 33.0 (n¼ 34) 23.2 (n¼13) 0.14
Alcohol use (%) 56.2 (n¼ 58) 60.0 (n¼32) 0.58
SSRI use (%) 30.1 (n¼ 31) 20.4 (n¼11) 0.19
Right handed (%) 91.3 (n¼ 94) 94.4 (n¼51) 0.48
Childhood abuse indexa 1.59±1.96 1.65±2.27 0.87
Type of childhood abuse
Emotional abuse/neglect (%) 52.7 (n¼ 54) 52.3 (n¼28) 0.95
Sexual abuse (%) 13.6 (n¼ 14) 15.9 (n¼9) 0.94
Physical abuse (%) 11.0 (n¼ 11) 11.4 (n¼6) 0.94
Diagnostic status 0.78b
Healthy controls (%) 20.4 (n¼ 21) 18.5 (n¼10) 0.78
Depression (%) 26.2 (n¼ 27) 29.6 (n¼16) 0.65
Anxiety (%)c 19.4 (n¼ 20) 22.2 (n¼12) 0.68
Depression and anxiety (%)c 34.0 (n¼ 35) 29.6 (n¼16) 0.58
Depression severity, MA˚DRS 11.67±8.83 13.62±11.65 0.23
Anxiety severity, BAI 11.79±9.19 13.34±11.23 0.84
Abbreviations: BAI, Becks Anxiety Inventory; MA˚DRS, Montgomery A˚sberg Depression Rating Scale; SSRI, selective serotonin reuptake inhibitor.
aRange 0–8.
bP-value for the omnibus w2 (3 degrees of freedom) for differences in distribution of the met allele over diagnoses.
cIncluded a diagnosis of social phobia, panic disorder, generalized anxiety disorder and/or agoraphobia.
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were not observed. Voxel-wise analyses located the peak
voxel of the interaction between negative vs neutral
encoding val66met cluster at the left posterior
hippocampus ((x¼21, y¼27, z¼6), F1,461¼ 14,11,
Z¼ 3.55, PFWE_ROI¼ 0.024, K (number of voxels)¼ 15).
Exploratory voxel-wise whole brain analyses showed no
statistical significant effects of val66met and val66met–word
valence interactions in brain areas other than the
hippocampus at the a priori set threshold of Po0.05, FWE
corrected (see Supplementary Tables 2 and 3).
Regression analyses were used to evaluate whether the
higher hippocampal activity during the encoding of negative
words were moderated by the effects of abuse or diagnostic
status. Hippocampal encoding activity in response to words of
negative valence was higher in abused subjects as compared
with non-abused subjects (B¼ 0.16, 95%CI¼ 0.05–0.28,
P¼ 0.007). In addition, we found a val66met–childhood abuse
interaction (B¼0.10, 95%CI¼0.17 to 0.02, P¼ 0.01)
showing that childhood abuse predicted increased hippocam-
pal activation in response to negative words in val/val
homozygotes (P¼ 0.009) but not in carriers of a met allele
(P¼ 0.34) (see Figure 2b). Effects of psychiatric status
(lifetime and current) and val66met by psychiatric status
interaction effects were not observed (all P’s40.10). Adding
memory accuracy as a predictor to the model did not change
our results (data not shown) making it unlikely that these
results are accounted for by genotype differences regarding
attention or effort.
Discussion
We addressed the effects of val66met on hippocampal volume
and function while taking into account the possible confound-
ing effects of childhood abuse and psychiatric status.
In line with some previous studies,17–19 but not all (for
example, ref. 26) we find smaller hippocampal volumes in
carriers of a met allele relative to val/val homozygotes. This
effect has generally been explained by abnormal intracellular
trafficking and impaired activity secretion of BDNF and by
extension aberrant trophic support in carriers of a met allele
relative to the val/val homozygotes that have been shown in
in vitro experiments.11,12 As atrophy of the hippocampus has
also been associated with (early) stress and/or a current or
remitted depressive episode,4 it is crucial to exclude the
possible confounding effects of these variables. Our data
suggest that the association between the met allele and
Table 2 Cerebral and hippocampal volumes and hippocampal-related encoding activity (mean±s.e.m.) by BDNF genotype and word valence (neutral, positive and
negative)
val66val (n¼103) val66met (n¼ 54) P-value
Total gray matter volume (ml)a 736.57±5.35 731.66±7.45 0.60
Hippocampal volume (ml)a,b
Total 6.45±0.03 6.31±0.04 0.02
Right 3.06±0.02 2.99±0.02 0.01
Left 3.39±0.02 3.31±0.02 0.05
Hippocampal encoding activitya,c,d
Neutral words 0.15±0.04 0.16±0.06 0.92
Positive words 0.15±0.05 0.23±0.07 0.32
Negative words 0.20±0.05 0.36±0.06 0.05
aAll mean values are corrected for gender, age, years of education, selective serotonin reuptake inhibitor and alcohol use and site of scanning.
bMean values are additionally corrected for total cerebral grey matter volume.
cValues are expressed as change vs baseline and thus are in arbitrary units.
dMean values are additionally corrected for total hippocampal volume.
Figure 2 (a) Mean total hippocampal activity during encoding by stimulus valence for subjects homozygous for the val allele (val/val, n¼ 103) and carriers of a met allele
(val/met, n¼ 54). (b) Mean total hippocampal activity during the encoding of negative words by childhood abuse before the age of 16 years (yes vs no) for subjects
homozygous for the val allele (55 abused, 48 non abused) and carriers of a met allele (25 abused, 29 non abused). The val66met–childhood abuse interaction effect is
significant at P¼ 0.01. Error bars reflect the s.e.m. Data are adjusted for age, gender, number of years of education, selective serotonin reuptake inhibitor use, alcohol use and
scan site. *Po0.05.
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hippocampal volume is independent of childhood abuse. This
finding is at odds with those of Gatt et al.,28 who modeled the
interaction of early life stress and val66met in the prediction of
hippocampal volume and found that the combination of
carrying a met allele and being exposed to early life stress
was associated with smaller hippocampal volumes in healthy
adults. It could be that the observed discrepancy between the
results of Gatt et al.28 and ours might be explained by a
broader definition of early life stress by Gatt et al.28 who
included, for example, also illness and exposure to natural
disasters as stressful events, whereas we focused on child-
hood abuse including physical, sexual and emotional abuse.
Furthermore, Gatt et al.28 studied healthy control subjects,
whereas we studied mostly patients. However, exactly how
these differences between the studies could have led to a
different pattern of results is unclear. In line with Frodl et al.,19
we show that lifetime and current psychiatric status does not
thrive the val66met genotype effect on hippocampal volume,
providing evidence for a direct association between the met
allele and small hippocampal volume that further appears to
be specific to the hippocampus.
In addition to reduced hippocampal volume, we show that
val66met interacts with word valence such that encoding
activity is increased in carriers of a met allele during the
negative word condition and not in the neutral or positive word
condition. This effect was not observed in other brain areas
than the hippocampus and is consistent with studies in which
emotional stimuli were used,24,25 but not with studies in which
neutral stimuli were used.50 We could not replicate the finding
of higher hippocampal activation in carriers of a met allele in
response to neutral stimuli as is reported in the seminal study
by Egan et al.12 On the basis of a recent study that showed
that negative affectivity increased more in response to social
stress in met carriers as compared with val/val homozy-
gotes,51 one may speculate that carriers of a met allele are
more sensitive or reactive to negative stimuli. Owing to a
possible relation between higher hippocampal activity and
psychopathology,52,53 this finding might concur with studies
that show a link between the met allele and depression
(reviewed in ref. 53). We further found, in line with some
studies that childhood abuse predicts higher levels of
hippocampal encoding activity.52–54 However, from our data
it appears that childhood abuse is associated with a relative
increase in hippocampal activity in val/val homozygotes only
and not in carriers of a met allele. Although speculative, an
interpretation may be that higher levels of hippocampal
activity after exposure to childhood abuse in val/val homo-
zygotes reflect a higher sensitivity for emotionally negative
stimuli in that in carriers of a met allele is present regardless of
exposure to childhood abuse. This idea is in line with studies
that report hippocampal dysfunction in various severe
psychiatric illnesses, particularly if exposure to childhood
abuse is documented.4,52–55
Despite differences in hippocampal volume and activity
between val/val homozygotes and carriers of a met allele we
did not find differences in memory accuracy and clinical
variables (for example, depression severity) as a function of
BDNF genotype. This may suggest on the one hand that our
findings are relevant for both healthy individuals and patients.
Moreover, it is pertinent to the debate on the relationship
between hippocampal volume and function with behavioral
performance. In line with the absence of associations
between hippocampal volume, hippocampal function and
memory performance in our study, a recent review on 80
studies showed that the model: ‘a bigger brain structure -
greater brain response - better performance’ may not
reflect reality.56
A notable strength of our study is that the findings are
derived from a genetically homogeneous sample and it thus is
unlikely that our results are devoid by population stratifica-
tion.57 Furthermore, we studied the effects of val66met in the
context of childhood abuse and emotional valence of stimuli,
and our results clearly highlight the importance of including
such variables. A few weaknesses of our study also merit
attention. Obviously, we cannot exclude the possibility that
other polymorphisms on the BDNF gene or on other genes,
notably those that constitute the neurotrophic pathway (for
example, CREB1 and NTRK2)29 might have contributed to the
effects that we observed. With regard to our self-reported
measurement of childhood abuse, it should be noted that the
validity and reliability of recall might vary by diagnosis and
time since abuse took place. Furthermore, in the face of
negative findings, statistical power is important to take into
account. Overall we had a comparatively large sample size,
but our analysis on psychiatric status might have been
underpowered particularly because the size of the control
samples may have been too small (for example, only 31
healthy control subjects) to detect effect sizes that are
reported to be moderate at best.58,59 Finally, although we
speculate that carriers of a met allele are more reactive to
emotionally negative laden stimuli as compared with val/val
homozygotes we are not able to confirm this because we have
no subjective ratings of the stimuli by our participants.
In sum, our results suggest that BDNF val66met has a small
effect on hippocampal volume and this effect appears to be
independent of childhood abuse and psychiatric status.
Furthermore, gene–environment interactions between
val66met and childhood abuse account for individual differ-
ences in hippocampal encoding activity of negative stimuli.
Important venues for future research are to delineate the
exact mechanisms, in vivo, through which the met allele
produces its effect on hippocampal volume and function. In
addition, it remains to be investigated, in longitudinal designs,
whether or not the effects of val66met on hippocampal volume
and activity are predictive for individual cognitive functioning
and psychological well-being.
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